Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The systemic sclerosis market size is expected to grow at a CAGR of 6.3% during the forecast period of 2024-2032. The growth of the market in the seven major markets is driven by increased research and development efforts to provide effective treatment alternatives to patients, along with growing focus on offering patient centric care.
Systemic sclerosis (SSc) is an autoimmune disorder that involves skin tightening and hardening due to excessive collagen production in the body. It first affects the fingers, hands, feet, and face. Raynaud’s phenomenon is also common and observed in more than 95% of the people with the condition. It occurs due to exaggerated contraction of small blood vessels in toes and fingers in response to cold or emotional distress.
The global incidence of systemic sclerosis is estimated to be 8.64 per 100,000 people annually. The prevalence is relatively higher in high income level countries. Adult females are more prone to develop the condition than males with an average of 5:1 .Children and teens below 15 years of age are less susceptible to the disease. The systemic sclerosis market demand is driven by increasing drug development activities and a subsequent growth in approvals from the regulatory authorities.
Surge in FDA Approvals to be a Key Driver
The market growth is driven by the increasing number of drug approvals developed by employing the latest technologies. In October 2023, Kyverna Therapeutics’ new investigational drug called KYV-101 received the application approval by the FDA for treating scleroderma. It is an autologous fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy aiding deep B cell depletion.
In February 2023, ChemomAb Ltd.’s new investigation drug for systemic sclerosis called CM-101 gained FDA clearance as per the results of phase 2 trials conducted in adults. CM-101 is a monoclonal antibody designed to interfere with vital biological pathways that are related to SSc. It has been well tolerated and helped with inflammatory reduction in patients.
Emphasis on Developing Effective Drugs that Address Disease Complications
Managing complications and side-effects is one of the major systemic sclerosis market trends. Interstitial lung disease (ILD) is a leading cause of death in systemic scleroderma disease affecting approximately half of the patients. To combat the number of mortalities associated with SSc-ILD, Benlysta (belimumab) , a B-cell inhibiting monoclonal antibody developed by GSK plc has been granted orphan drug designation (ODD) by the FDA in February 2023. It is the first and only approved biologic for the condition and can be administered to the pediatric population as well. The newly assigned status is aimed at offering further research to address a wider section of patients suffering from the condition.
Development in Non-Pharmacological Interventions
The growing application of alternative therapeutics is also expected to boost the systemic sclerosis market growth globally. Along with pharmacological interventions, haematopoietic stem cell transplantation (HSCT) is another treatment option for severe systemic sclerosis. Physiotherapy, occupational therapy, diet, psychology, and podiatry are some of the common management techniques suggested by the European Alliance of Associations for Rheumatology (EULAR).
Market Breakup by Diagnosis
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by End User
Market Breakup by Region
The United States is a major market with a robust medical ecosystem that works continuously to improve the therapeutic options available in the market. The presence of key healthcare providers also drives the market growth in the region. In October 2023, Certa Therapeutics’ systemic sclerosis candidate FT011 gained FDA’s orphan drug designation. It demonstrated clinically meaningful improvements for over 60% of the patients after 12-week treatment.
Europe is among the largest markets for systemic scleroderma with a substantial portion of geriatric population which is more prone to developing the condition. Having several academic and well-equipped research institutions at home also boosts the systemic sclerosis market growth. Mergers and acquisitions between vital pharmaceutical companies to adopt better technologies and develop effective solutions is a major market trend in the region.
In the Asia Pacific region, Japan is a leading region with the largest systemic sclerosis market share. However, other regions such as Australia, China, and India are also emerging as a prominent market with the help of growing investments in the region. For instance, ‘Shine Like a Sunflower’ funding drive in Australia aims to raise a significant amount to facilitate a cure and improve treatment in patients.
In April 2023, Merck & Co. acquired Prometheus Biosciences for a USD 10.8 billion to expand their immunology drug pipeline. Prometheus’ lead candidate, PRA023, a humanized monoclonal antibody is aimed at treating several autoimmune conditions including Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). Such mergers and acquisitions are a frequent occurrence in the market, especially with larger companies showing keen interest in small biotech firms to adapt their latest technologies and develop effective solutions.
The key features of the systemic sclerosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Diagnosis |
|
Breakup by Type |
|
Breakup by Drug Class |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032, driven by rising research and development efforts to provide effective therapeutic options to patients, along with increased emphasis on offering patient centric care.
The market demand is primarily driven by growing focus on developing alternate therapies that help patients with a wide spectrum of symptoms and addressing internal organ related complications.
The major market trend involves rising clinical trials and approvals to explore multiple therapeutic approaches including targeted therapies and immunosuppressive drugs. In October 2023, a new investigational drug called KYV-101 developed by Kyverna Therapeutics’ received application approval by the FDA for treating scleroderma.
The types of sclerosis can be divided into limited systemic sclerosis, diffuse systemic sclerosis, and sine systemic sclerosis.
Based on drug class, the market is divided into immunosuppressors, PDE-5 Inhibitors, endothelin receptor antagonist, and prostacyclin analogues, among others.
Major diagnosis methods include skin biopsy, imaging techniques, blood tests, electrocardiograms, and pulmonary function tests.
Major end users include hospitals, research institutes, and clinics, among others.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are F. Hoffmann La Roche Ltd., Johnson & Johnson Services, United Therapeutics, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Pfizer, Eli Lilly and Company, Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc, Novartis AG, Organon LLC, Lupin Ltd., and Cumberland Pharmaceuticals.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124